Matthew D. Galsky, MD - The Therapeutic Transformation of Bladder Cancer: Understanding Immune-, Targeted-, and Antibody-Based Models for Patient Care - a podcast by PVI, PeerView Institute for Medical Education
from 2021-06-21T18:00
Go online to PeerView.com/EQF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in genitourinary malignancies discusses novel therapies for bladder cancer. Upon completion of this activity, participants should be better able to: Cite the regulatory status and treatment roles of novel therapeutic classes in the management of urothelial cancer, Summarize updated evidence on the use of novel therapies, including immune checkpoint inhibitors, targeted therapies, and antibody–drug conjugates, across the spectrum of bladder cancer settings, Integrate novel therapeutics into management protocols for bladder cancer, including in the context of a clinical trial, Manage unique adverse events associated with novel immune-, targeted, and antibody-based treatments for bladder cancer.
Further episodes of PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Further podcasts by PVI, PeerView Institute for Medical Education